Overcoming challenging targets in antibody discovery
Webinar Overview:
Unlock solutions for your most challenging targets with this webinar that demonstrates how Alloy Therapeutic’s precision approach to antibody discovery delivers results. This technical discussion explores:
- The power of hyperimmune mice: Benefit from ATX-GKH’s enhanced immune responses that produce higher serum titers and increased lymphoid cell output, especially valuable for high homology
- Streamline your bispecific development: The common light chain Mouse platform (ATX-CLC) solves the HC/LC pairing challenge with kappa-based restricted light chain strains selected for flexibility in heavy chain pairing and ideal developability profiles- eliminating compatibility concerns.
- Real-world success against complex membrane proteins: See firsthand how the Seqimmune™ platform effectively targets
CLDN18.2, a challenging multi-spanning membrane protein, and rapidly identified novel CLDN18.2-specific binders with comparable or better binding activity vs clinical comparator molecules.
Webinar sample above. To access the full video content, fill out the form below.
To access the full on-demand webinar, Tackling Tough Targets in Antibody Discovery, please submit the form below. Webinar will be available immediately upon submitting.
About the Speaker:
Thomas Vincent, MS
Senior Director, Antibody Discovery
Alloy Therapeutics
Thomas Vincent, MS is the Senior Director of Antibody Discovery at Alloy Therapeutics with an extensive background in spearheading drug discovery programs. Prior to joining Alloy, he served as a Senior Scientist at Aruna Bio and Regulus Therapeutics, where he managed in vitro lead discovery, assay development, and supported translational research for biomarker development. As Senior Research Scientist at Abeome Corporation for nearly six years, he was instrumental in advancing the company’s therapeutic pipeline and played a key leadership role in lead antibody identification across multiple therapeutic programs. His extensive experience includes pivotal positions at cBio, Agensys, and lonis Pharmaceuticals. Vincent received his MS at UC San Diego under Dr. Douglass Forbes, leading to a publication in Molecular Cell.